Syndrome of Lipodystrophy
Keywords:
HIV-associated lipodystrophy syndrome, HIV, Highly active antiretroviral therapy, CD4-positive T-lymphocites.Abstract
Introduction: HIV morbidity and mortality has substantially decreased with the use of HAART. The prevalence of lipodystrophy in HAART patients is greatly variable; clinically, the changes may be subtle at the beginning, with signs of central lipohypertrophy and peripheral lipoatrophy in early stages. When lipoatrophy affects the face and/or fat accumulates to the cervicodorsal region (buffalo hump), this is considered advanced lipodystrophy.Clinical case: female patient of black race, 43 years of age, diagnosed HIV-positive in July 1999. After several years of treatment, changes started to be noticed in her body constitution, with clear signs of lipodystrophy.
Conclusions: the syndrome of lipodystrophy constitutes an adverse effect of HAART in AIDS patients, causing morphological and metabolic alterations that affects adherence to the treatment. Aesthetic repercussions provoke psychological alterations that affect these individuals directly in the affective, social and working areas. More research is needed for more evidence about this syndrome. The proper evaluation by health care professionals of HIV patients consuming HAART is vitally important, in order to timely diagnose the syndrome of lipodystrophy and apply fitting methods of treatments.
Downloads
References
1. Viñas Martínez Arturo Luis, Oliva Venereo Dinorah de la Caridad, Noda Ortega Lizbet, del Río López Noriel, Cáceres Rodríguez Dagmiris, Herrera Wainshtok Ana Claribel. Características clínico epidemiológicas de las personas con VIH/SIDA en el municipio Arroyo Naranjo. 1988- 2008. Rev haban cienc méd [revista en la Internet]. 2012 Mar [citado 2012 Nov 07]; 11(1): 112-119. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2012000100014&lng=es
2. Programa Nacional de Prevención y Control de las ITS/VIH/sida. Reporte anual VIH/Sida 2008. La Habana: MINSAP; 2008 p. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1729-519x201200014&script=sciarttext
3. Hoffman C, Mulcahy F. Perspectives. En: Hoffman C, Rockstroh J, Kamps BS (editores). HIV Medicine 2008. Cologne: Flying Publisher; 2008. p. 89-93. Disponible en: http://scielo.sld.cu/scielo.php?script=sciarttext&pid=S0034-75152012000200008
4. Fernández Argüelles Rogelio Alberto, Gutiérrez Rentería César Cuautemoc, Castro Melchor Pedro, Flores García Aurelio, Cancino Marentes Martha Edith. Síndrome de lipodistrofia en pacientes con VIH/sida que reciben terapia antirretroviral de gran actividad en Tepic, México. Rev Cubana Farm [revista en la Internet]. 2012 Jun [citado 2013 Mar 06]; 46(2): 202-212. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152012000200008&lng=es
5. Ruane PJ. Atypical accumulation of fatty tissue [resumen I-184]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canadá, 1997.
6. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. JAIDS: Journal of Acquired Immune Deficiency Syndromes. [Internet] 2003 [cited cited 2013 Mar 11]; 33(5)71-6. Available from: http://www.medscape.com/viewarticle/460052
7. Tien C , Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): Methods, Design,and Sample Characteristics. Am J Epidemiol 2006 May;163(9):860-9. [cited 2013 Mar 11]. Available from:http://aje.oxfordjournals.org/content/163/9/860.full.pdf+html
8. Mallewa E et al. HIV-associated lipodystrophy: a review of underlying
mechanisms and therapeutic options. Journal of Antimicrobial Chemotherapy
[Internet] June 2008 [cited 2013 Mar 11]; 62:648-660. Available from: http://jac.oxfordjournals.org/content/62/4/648.full.pdf+html

Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/